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The International Stem Cell Initiative compared several commonly used approaches to assess
human pluripotent stem cells (PSC). PluriTest predicts pluripotency through bioinformatic
analysis of the transcriptomes of undifferentiated cells, whereas, embryoid body (EB) for-
mation in vitro and teratoma formation in vivo provide direct tests of differentiation. Here we
report that EB assays, analyzed after differentiation under neutral conditions and under
conditions promoting differentiation to ectoderm, mesoderm, or endoderm lineages, are
sufficient to assess the differentiation potential of PSCs. However, teratoma analysis by
histologic examination and by TeratoScore, which estimates differential gene expression in
each tumor, not only measures differentiation but also allows insight into a PSC’s malignant
potential. Each of the assays can be used to predict pluripotent differentiation potential but, at
this stage of assay development, only the teratoma assay provides an assessment of plur-
ipotency and malignant potential, which are both relevant to the pre-clinical safety assess-
ment of PSCs.
DOI: 10.1038/s41467-018-04011-3 OPEN
Correspondence and requests for materials should be addressed to P.W.A. (email: p.w.andrews@sheffield.ac.uk)
#A full list of consortium members appears at the end of the paper.
NATURE COMMUNICATIONS |  (2018) 9:1925 | DOI: 10.1038/s41467-018-04011-3 |www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
The capacity to differentiate into derivatives of all threeembryonic germ layers are the central defining feature ofall pluripotent stem cells (PSC), but assessing this property
remains a challenge for human cell lines. PSC were first recog-
nized as embryonal carcinoma (EC) cells in teratocarcinomas,
germ cell tumors that also contain a wide array of somatic tis-
sues1–4. In a classic experiment, using a teratocarcinoma of the
laboratory mouse characterized by Stevens5 Kleinsmith and
Pierce6 provided the first functional demonstration of plur-
ipotency by showing that single cells from ascites-grown
embryoid bodies (EBs) could generate tumors containing EC
cells together with somatic tissues. The connection between ter-
atocarcinoma and normal embryos was subsequently established
by experiments showing that embryos transplanted to extra-
uterine sites inevitably develop into teratomas or retransplantable
teratocarcinomas7,8. The discovery that murine EC cells can
participate in embryonic development when transferred to early
mouse embryos to give rise to chimeric mice9 led to the reali-
zation that EC cells have the developmental capacity of cells of
the inner cell mass. This laid the groundwork for the derivation of
embryonic stem (ES) cells from mouse embryos10,11 and later
from human embryos12 and of induced PSC (iPSC) from dif-
ferentiated human cells13,14.
In assessing mouse ES or iPS cell lines, pluripotency is func-
tionally defined from the PSC. However, for human PSC, be they
ES or induced pluripotent stem cells (iPSC) cells13,14, this fun-
damental assay is by the cell line’s ability, when transferred to a
preimplantation embryo, to form to a chimeric animal in which
all of the somatic tissues and the germ line include participating
cells not available. Moreover, a variety of well characterized PSC,
from both mice and primates have only a limited ability to par-
ticipate in chimera formation, even though they can differentiate
into tissues of all three germ layers in teratoma and in vitro
assays15. With the advent of technologies for producing large
numbers of human PSC16,17, some destined for clinical applica-
tions, the need for rapid and convenient assays of a specific PSC’s
pluripotency and differentiation competence has become
paramount.
The purpose of this study was to provide an authoritative
assessment of several established alternative techniques for
determining the developmental potential of human PSC lines.
The PluriTest® assay18 (www.pluritest.org), is a bioinformatics
assay in which the transcriptome of a test cell line is compared to
the transcriptome of a large number of cell lines known to be
pluripotent. This test can be carried out rapidly with small
numbers of cells, an important consideration in the early stages of
establishing new PSC lines. PluriTest is able to exclude cells that
differ substantially from undifferentiated stem cells, but does not
directly assess differentiation capacity. Complementing Plur-
iTest’s focus on the undifferentiated state, various methods have
been developed to monitor differentiation of the PSCs themselves
in vitro, including protocols that induce spontaneous differ-
entiation of cells in either monolayer or suspension culture, or
directed differentiation under the influence of specific growth
factors and culture conditions that promote the emergence of
particular lineages19,20. One of the most common approaches has
been the use of differentiation in suspension culture, when clus-
ters of cells undergo differentiation to form embryoid bodies
(EB), often with some internal structure apparent21. EB differ-
entiation has also been combined with gene expression profiling
and bioinformatic quantification of gene signatures, giving rise to
the pluripotency scorecard assay22. Further development of this
scorecard defined a panel of 96 genes that identified the differ-
entiation capacity of a given cell line more quantitatively than the
typical histology-based teratoma assay23. The teratoma assay has
long been regarded as the ‘gold standard’ for assessing human
PSC pluripotency. Not only do truly pluripotent cells generate a
very wide array of derivatives in these tumors, but they are also
often organized into organoid structures reminiscent of those that
appear during embryonic development24. However, both the
production of teratomas as xenografts, and their detailed analysis,
which requires appropriately trained specialists, is costly and time
consuming, and may be limited by concerns over animal welfare.
Moreover, the teratoma assay, as routinely performed, does not
yield quantitative information on lineage differentiation poten-
tial25, although gene expression analysis of the teratomas them-
selves can supply more definitive analysis.
In the current International Stem Cell Initiative (ISCI) study,
following discussion at an ISCI workshop attended by about 100
members of the human PSC research community, we carried out
a comparison of these approaches for assessing pluripotency by
conducting a series of assays with human PSC lines, both ES and
iPS cells. PluriTest was used to assess the transcriptome of the
undifferentiated cell lines. For the EB assay, we chose one widely
used approach, the ‘Spin EB’ system21 and used an adapted
lineage scorecard methodology22 to assess the results. The Spin
EB method provides for control of input cell number and good
cell survival, and allows for differentiation under neutral condi-
tions and under well-defined conditions expected to promote
differentiation towards ectoderm, mesoderm or endoderm. Dif-
ferentiation in teratomas was appraised by both histological
examination and by “TeratoScore”, a computational quantitation
of gene expression data derived from teratoma tissue26.
These blinded analyses, conducted by independent experts on
PSC-derived samples in four highly experienced laboratories,
shows that each of these methods can be used to indicate plur-
ipotency and that each is able to detect some variation in
developmental potential among the cell lines. The choice of which
method(s) should be used must be dictated by the biological
question posed and the future use of the PSCs in question. We
propose a schema outlining the choice of methodology for par-
ticular applications.
Results
Experimental design. To compare PluriTest, EB differentiation
and teratoma, assays under conditions that would reflect varia-
bility between laboratories and cell lines, four separate, expert
laboratories in four countries carried out these studies on each of
three different, independent PSC lines and a fourth cell line, H9
(WA09)12, which was common to all (Supplementary Table 1).
All the experimental material was processed centrally, with high-
throughput RNA sequencing (RNA-seq), quantitative real-time
PCR and histology, as well as bioinformatics analyses carried out
by single-specialized laboratories. In total, we compared results
from 13 PSC lines (seven ESC and six iPSC lines).
Genetic integrity. It has been suggested that karyotypically var-
iant PSC might be associated with persistence of undifferentiated
cells in xenograft tumors27,28. As an important adjunct to the
differentiation studies we took several approaches to assess the
genetic integrity of the cell lines. Prior to initiating the experi-
ments, the four test laboratories confirmed that the cell lines they
planned to use had normal diploid karyotypes, excepting
NIBSC5, which carried a gain of the chromosome 20q amplicon
that has been previously described29. Gene expression data also
permitted evaluation of the genetic integrity of the cell lines at the
time they were used in the experiments. Over- or under-
representation of specific regions of the genome in the undiffer-
entiated PSC lines was evaluated using expression karyotyping (e-
Karyotyping)30. Of the 13 cell lines, only one, the ES cell line
MEL1 INSGFP/w, showed an aberrant e-karyotype containing
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Fig. 1 Detection of chromosomal aberrations in PSC and tumors using e-Karyotyping and eSNP-karyotyping. a e-Karyotyping: each line depicts the moving
average plots of global gene expression in 13 different cell lines over 300-gene bins. The gene expression of 12 cell lines (black lines) was close to the total
mean, suggesting a normal karyotype. In contrast, all replicates of the MEL1 INSGFP/w (cyan) cell line showed considerable upregulation of genes from both
chromosomes 12 and chromosome 17, suggesting that it harbors an additional copy of these chromosomes. b eSNP-karyotyping: detection of chromosomal
aberrations in tumors using eSNP-karyotyping. Each line depicts the moving average (over 151 SNPs) of gene expression generated from RNA-seq data of
tumor derived from 13 different cell lines (one plot per source cell line). Colors represent tumor replicates. Only tumors derived from MEL1 INSGFP/w and
NIBSC5 show an altered allele ratio in both replicates, suggesting an aberrant karyotype with additional copies of chromosomes 17 and 12, respectively
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04011-3 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1925 | DOI: 10.1038/s41467-018-04011-3 |www.nature.com/naturecommunications 3
extra copies of chromosomes 12 and 17 (Fig. 1a). These dis-
crepancies from the test laboratories reports for NIBSC5 and
MEL1 INSGFP/w most likely reflect the sensitivities of different
assays for detecting low level genetic mosaicism31 and the pro-
pensity of variants to overgrow the culture rapidly once they
appear32. Consistent with this interpretation, the MEL1 INSGFP/w
is known to exhibit karyotypic instability in culture (RM, EGS,
and AGE, unpublished results). Because of the heterogeneous cell
composition of teratomas a different methodology is required to
evaluate the chromosomal integrity of the cells comprising them.
eSNP-karyotyping enables a direct analysis of chromosomal
aberrations by calculating the expression ratio of SNPs, making it
less sensitive to global gene expression changes between different
samples33. eSNP-Karyotyping of the teratomas indicated that
most remained karyotypically diploid, but also revealed that
teratomas derived from NIBSC5 had additional copies of chro-
mosomes 12 (and perhaps 20), and that teratomas derived from
MEL1 INSGFP/w carried an additional copy of chromosome 17,
but not chromosome 12 (Fig. 1b). Extra copies of human chro-
mosomes 12, 17, and 20 are recurrent changes in cultured PSCs,
and have also been reported in human germ cell tumors29. These
changes likely reflect a selective advantage conferred by extra
copies of genes on these chromosomes to cells grown either
in vitro or in vivo34,35. Taken together our results suggest that
cultures of NIBSC5 and MEL1 INSGFP/w, but of none of the
other 11 lines, were initially mosaic containing low levels of
variant cells.
PluriTest analysis. PluriTest was used to assess the molecular
similarity of the different undifferentiated cell lines to that of
other known PSC lines. RNA samples were analyzed using the
Illumina Human HT-12 v4 Expression BeadChip and subjected
to the PluriTest algorithm18. PluriTest generates two summary
scores from global gene expression profiles: a pluripotency score
that predicts whether a cell sample is pluripotent based on the
similarity of its gene expression signature to gene expression
profiles of a large collection of human PSC; and a novelty score
that detects the presence of gene expression patterns usually not
associated with human PSC. A pluripotent cell line is character-
ized as passing the PluriTest if it simultaneously exhibits a high
Pluripotency and a low-novelty score. If the scores of a test cell
line deviate from the empirically determined Pluripotency and
Novelty thresholds, the sample is flagged for further investigation.
As the original PluriTest algorithm was developed for an older
Illumina BeadChip platform, it was adapted to a new platform
using the H9 samples from all four laboratories as a control for
technical variation (Supplementary Fig. 1). Analyzing samples
with the updated PluriTest script, showed that at least one
replicate of most lines assayed passed both PluriTest criteria
(Fig. 2; Supplementary Fig. 1).
In the case of cell lines RM3.5 and Oxford-2, while we observed
high-Pluripotency Scores in both replicates (Fig. 2), there was a
large difference in the Novelty Scores between the two replicates,
placing one replicate above the empirical threshold for the
Novelty Score (1.67). A similar result was obtained for one of the
two replicates from the 201B7 cell line. The differences in Novelty
score observed between replicates could be due to technical
failures of the array hybridization, or it could reflect differing
extents of spontaneous differentiation in the cell line samples
analyzed. Nevertheless, we concluded that all cell lines with one
replicate below the empirical Novelty Score threshold passed
PluriTest and are predicted to have pluripotent differentiation
potential in vitro and in vivo. However, the PSC lines DF19-9-
11T.H and MEL1 INSGFP/w did not pass the empirically
determined Novelty Score threshold of 1.67, thus flagging them
for further investigation. Interestingly, the MEL1 INSGFP/w PSC
line did have an abnormal e-Karyotype (Fig. 1a, b), providing a
possible explanation for its borderline results in PluriTest.
Scorecard analysis of embryoid body differentiation in vitro.
The participating laboratories also subjected their cell lines to a
standardized embryoid body (EB)-differentiation protocol under
four different conditions: neutral, without the addition of exo-
genous growth factors that favored any particular lineage, and
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Fig. 2 Pluritest. a All PluriTest results from this study (red circles) are based on normalization to the H9 samples and were plotted on the background of the
empirical density distribution of all pluripotent (red cloud) and differentiated samples (blue clouds) in the PluriTest training dataset18. b–f highlight the
subsets of samples included in this study: All results from the same hPSC line (H9) cultured at each laboratory (b). Samples from Lab 1 (c), Lab 2 (d), Lab 3
(e), Lab 4 (f) are highlighted specifically. All cell lines are above the Pluripotency Score threshold (θP >= 20). Both replicates of two cell lines MEL1
INSGFP/w in d and DF19-9-11T.H in e score above the Novelty threshold (θN>= 1.67) and thus would be highlighted for further investigation. Three cell lines
show larger differences between the novelty scores of their respective replicate samples 201B7 in c, RM3.5 C in d, and Oxford-2 in f
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directed conditions designed to promote initial differentiation
into ecto-, meso-, or endoderm lineages, respectively21. It was
anticipated that these protocols would be sufficient to direct
differentiation toward the germ layer of interest but would not
necessarily support the generation of more mature cell types.
Lysates from the resulting EBs were examined by qRT-PCR at 0,
4, 10, and 16 days of differentiation for expression of 190 genes
(Supplementary data 2, 3) modified from the set used by
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Fig. 3 Differentiation potential and propensity in EBs. a The line plots show the mean log2 expression change (relative to day 0) of marker genes
(Supplementary table 3) as a function of time and averaged over all cell lines. The expression change is shown under ectoderm conditions for ectoderm
markers, mesoderm conditions for mesoderm markers, endoderm conditions for endoderm markers, and across all conditions for markers of
undifferentiated cells. Shaded contours indicate the minimum/maximum observed value. b A summary table of the lineage scorecard evaluation of the
“propensity” (spontaneous differentiation, left) and “potential” (directed differentiation, right) for each cell line (rows) to differentiate into the respective
lineage (columns). Colors and symbols indicate increased (blue) and limited (grading of lighter blues) preference for expression of lineage- specific marker
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the lineage score after 16 days of EB differentiation (“propensity”; x-axis) with the lineage score for teratomas derived from the same cell lines (y-axis). The
lineage scores for ectoderm (left), mesoderm (center), and endoderm (right) marker expression are shown separately
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Bock et al.22, to include genes characteristically expressed in
undifferentiated PSC, extraembryonic endoderm, trophectoderm,
early definitive ectoderm, mesoderm, and endoderm. For each
lineage and for undifferentiated cells, we picked an equal number
(n= 15) of marker genes for further analysis (Supplementary
Table 2), by focusing on those genes with the strongest lineage-
specific upregulation of genes in our dataset (Methods section).
These marker genes were generally more highly expressed in EBs
cultured under the corresponding differentiation conditions,
while expression of markers of undifferentiated cells gradually
dropped (Fig. 3a, Supplementary Fig. 2a). Gene expression was
least variable 4 days after induction of differentiation compared
to other time points (Supplementary Fig. 2b, c).
The lineage scorecard analysis was carried out as described
previously22 but with the refined gene set (Supplementary
Table 3) and with one conceptual extension: the “potential” of
cells to undergo differentiation into the three primary lineages
under directed differentiation conditions was distinguished from
their “propensity” to differentiate under neutral conditions. The
“potential” of a cell to differentiate into a certain lineage was
defined as the lineage score at 16 days of directed differentiation
culture conditions. That is, ectoderm induction was used for
ectoderm marker profiling, mesoderm induction for mesoderm
markers, and endoderm induction for endoderm markers. The
“propensity” (or inherent bias) of a cell line to undergo
differentiation was calculated from the lineage scores (Methods
section) of all marker sets after 16 days in neutral differentiation
conditions.
Scorecard analysis resulted in three key observations (Fig. 3b,
Supplementary Fig. 2a, b). First, in neutral culture conditions all
cell lines had the propensity to upregulate ectoderm markers, but
all cell lines also initiated mesoderm and endoderm expression
programs, though some (KhES-1, 201B7, RM3.5C, and H9 from
Labs 2 and 4) had reduced propensities to form one or both of
these latter lineages, an apparent bias not recapitulated in the
teratoma assay (Table 1 below). Second, ectoderm-inducing and
mesoderm-inducing conditions elicited strong, homogeneous
expression signatures consistent with the expected directed
lineage, while endoderm-inducing conditions elicited more
variable responses, depending on both the cell line and on the
laboratory, a result most marked in the Oxford-2 line. Third, the
data suggest that, overall, all cell lines were capable of
differentiating into representatives of all three lineages, although
there were differences in how well and how consistently the PSC
lines responded to these specific differentiation cues.
Differentiation in xenograft teratomas in vivo. Each laboratory
produced between one and three xenograft tumors from each cell
line, by subcutaneous injection into immunodeficient mice, as
described in Methods section (Supplementary Table 1). Although
a common protocol was suggested for tumor production, local
circumstances mandated some modifications to this protocol in
each case, particularly with respect to the particular strains of
mice used as hosts. After cutting each tumor into several pieces,
approximately half of them were randomly selected for histology,
while the other half was processed to provide RNA for RNA-seq
and TeratoScore analysis.
All PSC-derived tumors were classified as teratomas, since each
contained tissues identified as derivatives of the three germ layers
(Fig. 4a, b). Overall, a median of 10% (range, 5–30%) of the
differentiated tissues observed were of endodermal derivation,
40% (range, 10–60%) represented tissues of mesodermal origin
and 45% (range, 10–80%) represented tissues of ectodermal
origin (Table 1 and Fig. 4c). Cells from all three embryonic germ
Table 1 Histology and teratoscore comparison of xenograft tumors
Xenograft Tumors
Histologya RNA-seq
Teratoscoreb
Lab Cell Line Cell 
Type
Ecto Meso Endo ECL YS Ecto Meso Endo Extra
Emb
ECL
/YSc
Lab 
1
H9 +++ + + – – nd nd nd nd nd
KhES-1 +++ + + + + ++ + + + +
201B7 +++ ++ + + + ++ + + ++ –
Tig108 4f3 ++ ++ ++ + + ++ ++ + ++ +
Lab 
2
H9 ++ ++ + – – ++ ++ +/++ + –
HES3 
MIXL1 GFP/w
+++ ++ + – – ++ ++ + + –
MEL1 
INS GFP/w
+ +++ ++ – – ++ ++ ++ ++ –
RM3.5C ++ +++ + – – ++ ++ ++ ++ +
Lab 
3
H9 + +++ + – – ++ ++ ++ ++ –
H14 + +++ + – + ++ ++ ++ ++ +
DF19-9-11T.H ++++ + + – + ++ +/++ +/++ +/++ +
iPS(IMR90)-4 +++ ++ + – – ++ ++ + + +
Lab 
4
H9 ++ +++ + – – ++ ++ ++ + –
Shef3 + +++ + – + ++ ++ + + +
Oxford-2 ++ ++ + – – ++ ++ ++ ++ –
NIBSC 5
ES
ES
iPS
iPS
ES
ES
ES
iPS
ES
ES
iPS
iPS
ES
ES
ES
iPS ++ ++ + – – +/++ ++ ++ +/++ –
a The presence of tissues scored as ectoderm (ecto), mesoderm (meso), endoderm (endo) in the histological examination of the tumors is summarized as median scores corresponding to the presence
of the respective germ layers: ‘+’ (0–25%), ‘++’ (25–50%), ‘+++’ (50–75%), and ‘++++’ (>75%)
b For Teratoscore, the percentage of ectoderm, mesoderm, endoderm, and extraembryonic specific-gene expression is summarized in comparison to the mean percentage of 4 pilot, karyotypically normal
teratomas: ‘+’ (the pilot expression mean) ‘++’ (similar to the pilot expression mean)
c The presence of undifferentiated cells (ECL) and/or yolk sac elements (YS), assessed by both histology and by RNA-seq analysis is indicated by ‘+’, in cells that are highlighted in yellow
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layers were found in the teratomas, derived from both ES
and iPS cell lines produced by each of the laboratories. Although
all teratomas contained derivatives of the three embryonic
germ layers, in fact only a fairly narrow range of tissues was
routinely identified. Neural tube-like structures, pigmented
epithelium and squamous epithelium accounted for most
ectoderm, cartilage, connective tissue, and bone for most
mesoderm, and glandular, ductal and intestine tissue for most
of the endoderm (Fig. 4c).
Some teratomas also contained areas of undifferentiated cells,
which we designated as embryonal carcinoma-like (ECL) cells,
some exhibited areas of yolk sac elements, and some contained
cells in some areas organized into EB like structures (Fig. 4d–f).
The histological identification of the ECL was confirmed by
H9-ESC ESC iPSC
Tissue Lab1 Lab2 Lab3 Lab4 Lab1 Lab2 Lab3 Lab4 Lab1 Lab2 Lab3 Lab4
Ectoderm
Neural 4/4 3/3 1/3 2/3 3/3 5/6 5/5 5/5 6/6 3/3 3/3 3/3
pig. epith. 4/4 3/3 1/3 2/3 4/6 3/5 1/5 4/6 1/3 1/3 1/3
sq.  epith. 2/3 2/3 4/6 2/3
choroid pl. 4/4 3/3
Mesoderm
3/3 1/3 1/3 1/3 4/6 3/5 1/5 4/6 1/3 2/3 3/3
Bone 1/3 1/3 3/6 2/3
Stroma 2/3
Fat 2/3
Mesenchy. 4/4 2/3 1/3 3/6 2/5 3/6 1/3
Muscle 2/3
Endoderm
Glands
Cartilage
4/4 1/3 2/3 3/3 2/6 2/5 3/5 2/6 1/3 1/3 1/3
Ducts 3/3 2/3 1/3 3/6 3/5 3/6
Intestine 1/3 2/5 2/5
c
g
Ect a
Mes
End
End
EndMes
Sq
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P
b
N
ECL d
N
ECL e
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f
N
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YS h
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Fig. 4 Histological evaluation of three embryonic germ layers and undifferentiated EC-Like and yolk sac elements in xenograft tumors. a Mucus secreting
intestinal-like epithelium (End-endoderm), neural tube rosettes (Ect-ectoderm), and intervening stroma (Mes-mesoderm) (×240). b Intestinal-like
epithelium (End-endoderm), surrounded by connective tissue, smooth muscle and fat cells (Mes-mesoderm). The left outer rim of mesoderm is lined by
intestinal-like epithelium (End-endoderm). To the left there is pigmented epithelium (P), corresponding to retina (Ect-ectoderm), and a nest of glycogen
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NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04011-3 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1925 | DOI: 10.1038/s41467-018-04011-3 |www.nature.com/naturecommunications 7
immunostaining for expression of OCT3/4 (POU5F1) (Fig. 4g)
and the yolk sac cells by immunostaining for ZBTB16 (Fig. 4h)36.
As expected, SALL4 expression was found in both yolk sac and
ECL cells37,38 (Fig. 4i). The initiating PSCs in teratomas may
differentiate into derivatives of mature elements of all three germ
layers, and into extraembryonic elements, such as yolk sac12, or
the PSCs may proliferate in which case they may be noted as ECL
cells, suggesting a potential malignant phenotype. In the clinical
pathology of germ cell tumors (GCT), embryonal carcinoma and
yolk sac elements are frequently found in malignant
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teratocarcinomas, (reviewed in ref. 4), while yolk sac and
immature neural elements are commonly associated with
malignant transformation in teratomas of childhood39–42. It has
been proposed that the experimental teratomas produced by both
mouse and human ES and iPS cells are more akin to GCT of the
newborn (type 1 GCT), than to those of the adult (type 2 GCT)43.
This distinction correlates with the diploid or near diploid
karyotypes of most ES and iPS cells, in contrast to the grossly
aneuploid karyotypes of human EC cells from adult germ cell
tumors. In the experimental teratomas at hand we find it
noteworthy that even when these potentially malignant elements
were observed, robust differentiation into tissues derivatives of all
three germ layers was also seen within the same tumor. Histologic
evidence alone does not permit a definitive conclusion as to
whether the finding of ECL cells intermingled with yolk sac
elements is indicative of the malignant potential of a subset of the
PSCs tested, but it is certainly a cause for concern. Although,
most teratoma histological sections include differentiated struc-
tures from the three embryonic germ layers, an elaborate analysis
of cell type would require further experimental investigation.
RNA samples were extracted from 44 of the 58 tumors
prepared. Of these, 35 samples passed the quality control tests for
RNA quantity, purity and integrity required for RNA-seq and
further analysis. These samples represented tumors derived from
12 different independent cell lines (6 ESC, 6 iPSC), as well as
tumors derived from H9 in three of the four laboratories. An
initial unbiased hierarchical clustering of all gene expression data
was performed (Fig. 5a). Although tumors derived from the same
cell line sometimes clustered together, sometimes they did not,
and data from tumors of the different cell lines, be they ES- or
iPSC-derived, as well as those from H9-derived tumors, even if
from the same laboratory, were scattered throughout the
dendrogram suggesting there was no obvious laboratory effect
(Fig. 5a).
To assess whether there were residual undifferentiated PSC
within the teratomas, we queried the RNA-seq datasets for
expression of ten undifferentiated PSC markers (Supplementary
Table 3). These marker genes were initially selected based on
results previously published by the ISCI44 and include several
markers also expressed by yolk sac endoderm cells45–47. When
expression of these genes in the teratomas was compared to that
of cultured undifferentiated PSC, their mean expression was
found to be 2.5% of that in the PSCs (Supplementary Table 3).
Nevertheless, eleven teratoma samples, originating from
seven different PSC lines (KhES-1, TIG108 4f3, RM3.5,
H14, DF19-9-11T.H, IPS(IMR90)-4, Shef3), exhibited substan-
tially higher average expression levels of these 10 markers,
suggesting the presence of undifferentiated PSCs and/or yolk
sac elements (Fig. 5b). Those teratomas showing elevated
expression of these marker genes also clustered in a principal
component analysis (Supplementary Fig. 3). Of these lines,
TIG108 4f3 had been previously classified as ‘differentiation
defective’, and KhES-1 as ‘intermediate defective’, in an assay that
assessed the persistence of undifferentiated, OCT3/4+ (POU5F1)
cells after a defined period of specific neural induction in vitro48.
In concert with that report we noted that TIG108 4f3 tumors
showed higher levels of the stem cell markers than KhES-1
tumors (Fig. 5b). Teratomas derived from five of these seven cell
lines were found by histological analysis to contain ECL cells
(KhES-1 and TIG108 4f3) and/or yolk sac cells (KhES-1, TIG108
4f3, H14, DF19-9-11T.H, Shef3) (Table 1). Overall, these results
suggest that many of the teratomas contained differentiated
derivatives of extra-embryonic membranes and potentially ECL
cells.
The TeratoScore algorithm enables the use of teratoma gene
expression to provide a quantitative analysis of the ability of a
PSC line to differentiate26. This analysis quantifies tissue-specific-
gene expression within heterogeneous PSC-derived teratomas,
thus providing an estimation of teratoma tissue composition.
Since TeratoScore was originally designed for microarray analysis,
it was adapted in this study to analyze RNA-seq data. Similar to
the original TeratoScore calculation, a 100-gene signature was
created by identifying genes expressed in teratomas and specific
to tissues representing derivatives of the three embryonic germ
layers and the extra-embryonic membranes (Methods section;
Supplementary Data 4). Comparing expression of these genes in a
teratoma to their respective expression level in normal tissues
provides an estimate for the existence of cells from each tissue
within the tumor, as well as a lineage expression proportion. By
calculating the expression values from the different lineages, the
TeratoScore provides a unified grade that weighs the different
tissue-specific expression within a teratoma and provides an
estimate of the ability of a PSC line to differentiate (Methods
section). As expected, each individual normal tissue yielded a
high-expression level of its specific cell type and lineage
(Supplementary Fig. 4), yet a low unified TeratoScore grade
(Fig. 5c). In contrast, teratomas show a relatively high score for all
cell types (Supplementary Fig. 4) and lineages, and also higher
TeratoScore grades (Fig. 5c). A TeratoScore grade >10 was
deemed sufficient to determine that a given tumor was initiated
from a PSC line capable of differentiating toward derivatives of
three germ layers in a relatively evenly distributed fashion, since
no normal tissue exceeded this threshold (Fig. 5c). However, of
the 35 teratomas tested, six samples originating from three PSC
lines (Shef3, KhES-1, and HES3 MIXL1GFP/w) did not reach this
threshold (Fig. 5c). A closer look at the expression patterns from
these teratoma samples revealed higher expression of neuroecto-
dermal markers in KhES-1 and HES3 MIXL1GFP/w compared to
Fig. 5 Teratoma RNA-seq expression data analysis. a Unsupervised hierarchical clustering analysis of RNA-seq expression of teratomas from four different
laboratories (calculated using complete linkage and Spearman correlation distance). Tumors from the same laboratory appear in the same color. Label
numbers (T1, T2, etc.) indicate teratoma replicates. Specific RNA-seq sample identifiers are indicated below the sample names. bMean relative expression
of human undifferentiated PSC/yolk sac markers within teratomas and normal tissues calculated with respect to their expression in PSCs. Eleven teratomas
(highlighted by colored dots) showed an expression greater than teratoma overall average (2.5%). c TeratoScore grades, calculated from RNA-seq profiles
of normal tissues and teratomas. Each grade represents expression of markers from the three embryonic germ layers and extra-embryonic membranes.
Normal tissues provided a mean grade of 2.7 ± 0.2, while teratomas provided a mean grade of 145.0 ± 61.6. Six teratomas from three lines (Shef3, KhES-1 or
HES3 MIXL1GFP/w) provided a grade lower than 10, the threshold reflecting sufficient representation of all lineages. Samples with a low TeratoScore grade
are highlighted. d Distribution of aberrant tissue expression in teratomas. Shef3- derived teratomas show a low expression of endodermal and placental
markers, whereas KhES-1 and HES3 MIXL1GFP/w teratomas show high expression of ectodermal markers and low expression of all other lineage markers.
Arrows designate lineages with distinctly low expression (<4% of mean expression ratio). (TSG: TeratoScore Grade; Ect: Ectoderm; Mes: Mesoderm; End:
Endoderm; CPNS: Central and Peripheral Nervous System; Adip: Adipose Tissue; Kdny: Kidney; Mscl: Skeletal Muscle; Bld: Blood; Panc: Pancreas; Plac:
Placenta; Undf: Undifferentiated Markers; ExEm: Extraembryonic). Error bars represent SEM
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all other lineages and lower expression of endodermal markers in
Shef3 compared with the other lineages (Fig. 5d).
Comparing these data with those from histologic analysis, we
find that ectoderm-derived tissues were also found at moderately
high levels in KhES-1 and HES3MIXL1GFP/w teratomas (Table 1).
The rather low levels of endoderm-derived tissues in Shef3-
derived teratomas were also confirmed by histologic analysis.
However, the high-ectoderm content for DF19- 9-11T.H-derived
tumors seen in tissue sections was not flagged by the TeratoScore
assay. Histological analysis has a long and well accepted history in
anatomy and clinical practice, and is aided by the propensity of
cells within teratomas to form organoid structures that may be
more readily recognized than individual isolated cells. On the
other hand, TeratoScore, based on analysis of RNA-seq data, has
the potential to reveal the presence of a wider range of cell types,
such as those that do not form readily identifiable structures.
However, in the absence of an all-inclusive histological atlas of
gene expression in all developmental stages from embryo to
adult, TeratoScore could under- or over-estimate lineage
composition depending on the particular tissues present.
The micro-anatomical heterogeneity of teratomas presents a
drawback for both approaches since the number of tissue sections
that can practically be viewed is often limited; whereas, the
sensitivity of RNA-seq suggests that cell types present in small
proportions will be missed. Nevertheless, there was a good degree
of concordance between the two approaches on samples from the
same teratomas when identifying cells from the three embryonic
germ layers.
On the other hand, there was not much agreement between the
in vitro EB assays and the teratomas, assessed by both histology
and TeratoScore, in uncovering any apparent lineage bias of
individual PSC lines. RNA from the teratoma samples was also
analyzed by qRT-PCR using the same gene panel as for the EBs.
In general, there was little concordance between the expression
patterns of these genes in the EBs and teratomas derived from the
corresponding PSC lines; even at 16 days of EB differentiation the
teratomas did seem to show a higher tendency toward endoderm
differentiation than the corresponding EBs (Table 1, Fig. 3c). This
appeared to be the result of high expression of particular
individual marker genes (foremost GCG and FABP2; see
Supplementary Fig. 2d) and may not actually correspond to the
presence of differentiated endodermal tissues, which was low
according to the histologic analysis (Table 1). There was also no
concordance between the persistence of undifferentiated stem
cells in the teratomas (Table 1) and their persistence in the EBs
after 16 days of differentiation (Supplementary Fig. 5): for
example, although EBs formed under neutral conditions from
KhES-1, HES3 MIXL1GFP/w, H9 (Lab 1) and TIG108 4f3 showed
evidence of similar levels of persisting undifferentiated cells, ECL
cells were only identified in KhES-1, TIG108 4f3, and 201B7
tumors. Moreover, in the same EB-formation conditions KhES-1,
201B7, RM3.5C, and H9 (from Labs 2 and 4) had reduced
propensities to form mesoderm and endoderm, an apparent bias
not recapitulated in the teratoma assay (Table 1). Indeed, there
was a tendency for the teratoma assays to highlight even greater
ectodermal and less endodermal differentiation than the EB
assays. Differences in the in vitro versus the in vivo environment,
and in the timeline of the assays, likely account for these
discrepancies. That is, xenograft tumor formation takes place over
a number of weeks, after potentially undergoing complex
interactions, both within the tumor and between the tumor and
host tissue, whereas EB assays are performed within days of their
formation and therefore assess much earlier stages of differentia-
tion. Nonetheless, these two analytical approaches provide
complementary information of pluripotency and differentiation
potential.
Discussion
In this global collaboration, under the auspices of the ISCI, we
have compared three types of assay that featured independent
in vivo and in vitro analyses of samples prepared under stan-
dardized conditions in four highly experienced laboratories to
assess the developmental potential of human PSCs. Each of these
approaches does provide evidence of pluripotency, but each
measures quite different endpoints, each with its own distinct
limitations, and each provides markedly different insights into the
behavior of the cells. PluriTest provides a good and facile
screening tool to identify cell lines that deviate sharply from a
pluripotent gene expression profile. The capacity for PluriTest to
be readily revised, refined, and updated, as it was in this study,
could be seen as an advantage, particularly as the technology for
transcription profiling and bioinformatics analysis evolves. The
assay was developed for predicting teratoma formation based on
whole-genome analysis, but provides no direct information on
potential differentiation biases, and has not been shown to
identify cell lines that display signatures of malignancy. In vitro
differentiation assays combined with bioinformatics scorecard
analysis of genes representative of the three embryonic germ
layers, provide a simple and direct biological readout. In contrast
to the in vivo teratoma assays, such in vitro tests provide quan-
titative information on differentiation potential that can be
readily assessed in an unbiased fashion and do not require a
specialist for histologic interpretation. On the other hand, like
PluriTest, these assays are currently unable to identify cell lines
that show biological behavior similar to that of transformed cells.
Prior to the emergence of large scale efforts to derive human
iPS cells the teratoma assay was regarded as the gold standard in
the field. The assay provides unequivocal evidence of a stem cell’s
capacity to differentiate (the formation of a wide range of tissues
is monitored directly, as is the capacity for tissues to undergo
histotypic organization). Due to the length and cumbersome
nature of the assay and its requirements for animal usage and
expert pathological assessment there are real limitations of the
teratoma assay as a routine screening tool, and in practice, in this
study and that of Bouma et al.49, teratoma formation did not yield
any greater discrimination concerning the differentiation poten-
tial of PSC lines than the in vitro assays. However, the teratoma
assay was the only one which provided evidence of malignant
potential of some of the PSCs. This is an important parameter
that impacts on both the experimental and clinical use of the cells.
Though the presence of undifferentiated stem cells, yolk sac
elements and primitive neuroectoderm are indicative of malig-
nancy in clinical germ cell tumor histopathology, their biological
significance has not been assessed in the context of PSC xeno-
grafts. Future studies could undertake the prospective isolation
and re-transplantation of such cells from xenografts, with a view
toward determining their potential for initiation of tumors with
histologic features of malignancy, including invasion and
metastasis. Furthermore, in the clinical setting of childhood germ
cell tumors, which resemble those derived from PSC, malignant
behavior can be attributed not only to undifferentiated PSC but
also to differentiated elements including yolk sac and primitive
neuroectoderm. Thus, while it is essential to eliminate undiffer-
entiated PSC from products destined for clinical use, safety
assessment must take into consideration the possibility of
malignancy arising from such differentiated tissues.
It is also interesting to note in this context that in contrast to
other studies in which correlations with karyotypic abnormalities
have been suggested to influence malignant potential28,50–53, no
such correlation was evident in the current study. Indeed, the
teratomas in which ECL cells and/or yolk sac were identified
derived from PSC lines with apparent diploid karyotypes. On the
other hand, PSC lines found to be mosaic for abnormalities, by
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karyotyping and/or e-Karyotyping, and teratomas shown to be
abnormal by eSNP-karyotyping, did not exhibit ECL cells and
robustly differentiated into derivatives of all three germ layers. A
causative relationship between genetic changes in PSC lines and
the presence of ECL, with or without yolk sac elements, in ter-
atomas requires further investigation and the significance of these
findings for future clinical applications remains to be established.
Based on our results, we suggest the choice of pluripotency
assay depends upon the level of assessment required for a parti-
cular application (Fig. 6). Analysis of gene expression in the
pluripotent state by PluriTest can be used as a screen to identify
rapidly cells that also meet other criteria of pluripotency. Plur-
iTest was designed to be continuously improved: as data from
well-characterized training sets of cell lines that show defective
differentiation or malignant behavior are added, PluriTest gains
power to discriminate subtler characteristics of pluripotent cells.
Meanwhile, if direct and quantitative confirmation of differ-
entiation capacity is required, we recommend in vitro sponta-
neous and directed EB differentiation combined with
bioinformatic scorecard analysis, which provides a rapid and
facile alternative to the teratoma assay, and one that can be
accepted as evidence of pluripotency for purposes of standard cell
line characterization. Further, consideration of indicator gene
panels taking into account key nodes in gene regulatory networks,
may provide better identification of differentiation outliers and
future assessment of the capacity for morphogenesis in 3D
organoid type cultures in vitro might also prove helpful. At
present, we suggest that, independent of other assays used to
characterize these cells, it is prudent to carry out the teratoma
assay on cells destined for clinical use. Cell banks should consider
this option carefully as a part of their standard characterization
protocol, particularly for widely used cell lines. The application of
TeratoScore provides a more quantitative approach to the readout
of the teratoma assay, compared to histologic analysis alone;
however, we strongly recommend further research efforts to
identify in vitro surrogate biomarkers indicative of malignant
potential. Future comparison of results from teratoma assays with
in vitro studies, and with genomic analyses of cell lines that yield
teratomas with malignant elements, may provide simpler
approaches, including in vitro surrogate genetic and epigenetic
biomarkers, to identify cell lines with malignant potential.
Methods
Cell culture. Each participating laboratory was asked to select three PSC lines
(Supplementary Table 1) to analyze together with a PSC line, H9 (WA09)12, that
was used in common in all laboratories. The cells were grown according to the
standard conditions typically used in each participating laboratory (Supplementary
Table 1).
e-Karyotyping. Gene expression profiles of the undifferentiated samples were
analyzed using Illumina HT12 microarray platform as described for PluriTest,
below. Annotations of the microarray platform probes were obtained from the
Illumina website (http://www.illumina.com/). Probe sets were organized by their
chromosomal location, and their expression values were log2-transformed. Probe
sets without annotated chromosomal locations were removed. An expression
threshold was defined according to the levels of the upper third highest expressing
probes, and probes with lower expression were elevated to this threshold. Probe
sets not expressed in over 20% of the samples were removed to decrease expression
noise. To obtain a comparative value, the median of each gene expression value
across all samples was subtracted from the gene’s expression value in each sample.
This median also served as a baseline to examine expression bias. The 10% most
variable genes, calculated by the sum of squares of relative expression value for
each gene, were removed during the analysis. Data were processed using CGH-
Explorer (http://www.softgenetics.com/CGHExplorer.html). A moving-average
plot was generated using the moving average fit tool, with windows of 300 genes.
eSNP-karyotyping. eSNP-karyotyping was performed as previously described33.
Briefly, RNA-seq reads were aligned to the genome (assembly version GRCh38)
using Tophat254 and SNPs were called using GATK HaplotypeCaller55. Called
SNPs were filtered by read number, with SNPs expressed in <20 transcripts dis-
carded, and minor allele frequency and allelic ratio (major to minor) was calculated
for the whole transcriptome. For visualization, moving medians of the major to
minor ratios were plotted along the moving medians of the chromosomal positions
using a window of 151 SNPs.
PluriTest. PluriTest analysis was performed as previously described18. We used
R3.2.1 together with lumi 2.20.2 and the original PluriTest workspace. Due to an
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Fig. 6 Proposed strategy to analyze new human pluripotent stem cell lines depends on the information required. To first determine whether or not a cell
line is pluripotent (orange lines), its signature can be compared to that of known pluripotent cells’ signatures using PluriTest. To confirm whether that cell
line (blue lines), is capable of differentiating into derivatives of all three embryonic germ layers in vitro embryoid body (EB) formation in ‘neutral’
differentiation conditions, or by specific lineage-promoting differentiation conditions, combined with bioinformatic scorecard analysis, should be sufficient.
If necessary differentiation to specific mature cells types may be also assessed in vivo by xenografting and teratoma formation followed by either
histological analysis or RNA-seq analysis using Teratoscore. But to evaluate whether the cell line in question might have malignant potential (green lines)
careful examination of histological sections of the teratoma using antibodies to specific markers or by focusing the RNA-seq and TeratoScore on specific
markers associated with a malignant phenotype is suggested
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overall shift in PluriTest results from experiments performed with newer versions
of the Illumina microarray platform, we added a correction-vector to the matrices
used in the computation of the Pluripotency and Novelty Scores. We used the
H9 samples available from all laboratories to correct the data toward the reference
H9 normalization target used in the original PluriTest algorithm (Supplementary
Figure 1). The shift-vector is simply the difference between the row-wise means of
the H9 samples in the current dataset and a H9 reference sample used as the
normalization target in the original PluriTest implementation18. Since, the shift-
vector is not restricted to positive data, we relax the non-negativity condition and
estimate the matrix calculation by replacing the multiplicative update used in the
original PluriTest workspace with a standard linear regression. The modified
algorithm was tested on the original training dataset to guarantee consistent results
(Supplementary Figure 1). The scripts required to run the analysis are provided via
the group GitHub repositories and PluriTest’s website (www.pluritest.org). The
PluriTest workspace is available at https://github.com/pluritest/pluritestCompared.
Production of size-controlled embryoid bodies. EBs were produced as previously
described56. Briefly, cells were trypsinized, counted and re-seeded in 96 well u-
bottomed plates at a density of 3000 cells per well in APEL media (Stem Cell
Technologies, Vancouver, CA) supplemented with factors for four differentiation
conditions: neutral (without any growth factors), ectoderm (10 μM dorsomorphin,
10 μM SB431542 and 100 ng/ml basic-FGF), endoderm (100 ng/ml Activin-A, 1 ng/
ml BMP4) and mesoderm (20 ng/ml Activin-A, 20 ng/ml BMP4) differentiation.
All growth factors were added once to the cultures at the onset of differentiation,
the medium was not changed and the EBs were left in suspension for the course of
the experiment. Biological replicates of each cell line were differentiated and har-
vested at three time points (4, 10, and 16 days) into RNAlater (Life Technologies,
USA) and stored at −80 °C for future use.
RT-PCR gene expression analysis. Total RNA was extracted and purified using
the PicoPure RNA Isolation Kit (Arcturus Bioscience) and QCed with a 2100
Bioanalyzer (Agilent Technologies). The high-capacity cDNA Archive Kit (Thermo
Fisher Scientific) was used to generate cDNA representative of the polyadenylated
transcriptome. Preamplification of cDNA was performed using the TaqMan Pre-
Amp Master Mix (Thermo Fisher Scientific) following manufacturer’s instructions
with 10 cycles of amplification. Each of the two sets of 96 Delta Gene assays were
pooled for priming of the preamplification reaction (i.e., two independent pre-
amplification runs for each RNA sample). Delta gene assays were designed and
provided by the manufacturer (Fluidigm) and are listed in Supplementary data 6, 7.
Real-time PCR was performed using these Delta Gene assays (Fluidigm), the
preamplified cDNAs, and 96.96 Dynamic Arrays (Fluidigm) run on a Biomark HD
Real-time PCR System (Fluidigm) following the Fast Gene Expression Analysis
Using EvaGreen protocol (User Guide PN 68000088 J1) provided by the manu-
facturer (Fluidigm). Cycle Threshold (Ct) values were calculated using the
instrument’s software (Application Version 4.1.2; Fluidigm).
Production of teratomas. Teratomas were generated in immunodeficient mice
according to a common protocol but necessarily modified to accommodate local
laboratory circumstances (Supplementary Table 1) and governed by local animal
experimental rules. After a suitable growth period, the tumors were excised and
divided into several pieces. To ensure representation across the tumor, a random
selection of half of the pieces of each tumor was placed in RNAlater (Life Tech-
nologies, USA) and frozen at −80 °C prior to shipping for RNA-seq analysis. The
remaining half of the pieces were fixed in 10% formal-saline prior to processing for
histological analysis.
Histological analysis. At least two different teratoma pieces were sampled from
each PSC line injected. Serial sections from 2 to 10 different pieces of each tumor
were examined by two investigators who estimated the amount of differentiation
into tissues derived from all three germ layers. The presence of yolk sac, embryoid
bodies (EB) and undifferentiated cells, classified as embryonal carcinoma-like cells
(ECL), were also noted.
Immunohistochemical staining. Sections (4 µm) from formalin-fixed, paraffin
embedded samples were subjected to immunohistochemical detection of ZBTB16,
SALL4, and OCT3/4 (POU5F1). Briefly, after deparaffinization and rehydration,
tissue sections were treated using either citrate buffer (ZBTB16) or Borg Decloaker
(SALL4, OCT3/4, Biocare Medical, Concord, CA) for 5 min in a pressure cooker
for antigen retrieval. Hydrogen peroxide (3%) was then applied to the sections to
quench endogenous peroxidase activity. Sections were then incubated with primary
antibodies against ZBTB16 (PLZF clone D-9; 1:50 dilution; Santa Cruz Bio-
technology, Santa Cruz, CA, USA), SALL4 (Clone 954–1054; 1:100 dilution; Bio-
care Medical, Concord, CA, USA) and OCT3/4 (Clone SEM; prediluted; Biocare
Medical, Concord, CA, USA) for 45 min. After extensive rinsing, all sections were
incubated with anti-mouse HRP-labeled polymer (EnVision TM+ System, Dako,
Carpinteria, CA, USA) for 30 min. Finally, the staining was visualized by DAB+
(Dako, Carpinteria, CA, USA). Immunohistochemical staining was performed
using the IntelliPATH FLX Automated Stainer at room temperature. A light
hematoxylin counterstain was performed, following which the slides were dehy-
drated, cleared, and mounted using permanent mounting media.
RNA-seq analysis. RNA was purified as described in RT-PCR analysis (below)
and the same teratoma RNA samples were used in both the RT-PCR and RNA-seq
experiments. RNA-seq libraries were prepared using the RNA sample preparation
kit v2 (Illumina) according to the manufacturer’s standard protocol. Briefly,
polyadenylated RNA was first purified from total RNA was first purified through
oligo-dT attached magnetic beads using two rounds of purification. Poly(A) RNA
was subsequently fragmented and primed with random hexamers for cDNA
synthesis. First strand cDNA synthesis was for 50 min at 42 °C using SuperScript II
reverse transcriptase. After second strand cDNA synthesis, multiple indexing
adapters were ligated, and libraries quality controlled with 2100 Bioanalyzer
(Agilent Technologies), normalized and pooled prior to sequencing. Libraries were
subjected to 101 base pair-end multiplex sequencing on an Illumina HiSeq 2000 in
high-output mode. Samples were multiplexed (7–8 samples per lane) resulting in
an average depth of 58 million reads per sample. Reads were aligned (human
reference genome hg19) and transcripts counted using Tophat and Cufflinks. Data
for analysis was expressed as FPKM values (Supplementary data 8, 9)
TeratoScore analysis. Since the original TeratoScore analysis26 was performed on
DNA microarray data, it was necessary to adapt the algorithm to the analysis of
RNA-seq data. Briefly, a 100-gene scorecard of tissue-specific genes representing
the three embryonic germ layers and extra- embryonic membranes was established
(Supplementary data 4). By comparing RNA-seq expression data of 14 human
body tissues, we identified genes with high tissue-specificity (expressing over 8-fold
higher in a given tissue, compared to the mean of all other tissues). The expression
of these genes was then compared between human PSCs and teratomas, validating
their enrichment in differentiated cells (expressing over fourfold higher in ter-
atomas compared to PSCs). Tissue specificity was finally validated using Amazonia!
(http://amazonia.transcriptome.eu), with a requirement for distinct tissue expres-
sion (an order of magnitude over all, or most, other tissues)57. The RNA-seq data
utilized in this analysis were obtained from the following sources: 13 human body
tissues were obtained from The Genotype-Tissue Expression project (GTEx, http://
www.gtexportal.org)58 (Supplementary data 5). A minimum of five samples from
each tissue was used to calculate a baseline expression, with samples chosen by the
shortest ischemic time and highest RNA quality (Supplementary data 5). RNA-seq
expression data for extra-embryonic tissues and human PSCs were obtained from
the NIH Sequence Read Archive (SRA) (http://www.ncbi.nlm.nih.gov/sra) (Sup-
plementary Data 5). Teratoma gene expression was obtained from 4 karyotypically
normal teratomas from the ISCI cohort (Supplementary data 5). Gene lists for
central and peripheral nervous system, and for small intestine and colon were each
merged together, as their specific-gene expression was similar. To generate the
TeratoScore output, average expression for each lineage was calculated as the mean
expression of all genes representing that lineage. TeratoScore grades were calcu-
lated as the multiplication of these means and dividing this product by 100.
RT-PCR analysis of EB differentiation. Data from all Fluidigm plates were col-
lected (Supplementary Data 2) and analyzed in R (https://www.r-project.org). Low-
quality datasets were removed (<33% of expected genes detected) and the raw Ct
values were capped at 35, scaled to the control genes (ACTB, GAPDH), quantile-
normalized59,60. To ease interpretation, we inverted the normalized numbers by
subtracting them from the maximum (Ct= 35), resulting in numbers in which
greater values represent stronger expression. For all further analysis and plots, we
selected 15 marker genes per lineage based on effect size during differentiation in
the EB assays (Supplementary Table 2). To this end, we calculated the rank of each
gene in the comparison between expression measurements at day 16 (compared to
day 0) per culture condition, taking the median across all cell lines. We then picked
the 15 top-ranked genes for each condition as markers for the respective lineage,
and the fifteen genes with the lowest average rank (i.e., those that were down-
regulated, on average, as response to culture conditions) as markers for undiffer-
entiated cells. Scorecard analysis was afterwards performed as previously
described22. Briefly, we calculated a parametric gene set enrichment analysis on
moderated t-scores for comparisons between each set of replicates (per cell line,
time and condition) and all data at day 0. We then used a modified gene set
enrichment analysis to examine the over representation of lineage markers in the
gene lists ordered by these t-scores61–63.
Data availability. The authors declare that all data supporting the findings of this
study are available within the article and its supplementary information files or
from the corresponding author upon reasonable request. Data from Illumina arrays
(Pluritest), Fluidigm PCR and RNA-seq experiments have been deposited in the
GEO database under accession code GSE97964.
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